Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
0 hedge funds and large institutions have $0 invested in Jounce Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $918K → $0 (-$918K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$918K |
JNCE Hedge Fund Activity: Q3 2023 in Review
0 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q3 2023, worth a combined $0 — down 100% from $918K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of JNCE and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Opaleye Management, exiting entirely with an estimated $918K sold.
- 0 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q3 2023, down from 1 in Q2 2023.
- Funds reported $0 of Jounce Therapeutics, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q3 2023 and 1 closed out, a net change of -1 holder.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q3 2023 was Opaleye Management, an estimated $918K sold.
Based on aggregated 13F filings for Q3 2023.